科华生物(002022) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥443,303,887.87, a decrease of 46.79% compared to ¥833,147,693.69 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥28,821,454.12, representing a decline of 152.63% from a profit of ¥54,761,876.98 in the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥39,116,563.64, down 181.25% from ¥48,141,247.97 in the same period last year[4] - Total operating revenue for Q1 2024 was CNY 443.30 million, a decrease of 46.7% compared to CNY 833.15 million in the same period last year[16] - Net profit for Q1 2024 was a loss of CNY 21.68 million, compared to a profit of CNY 97.17 million in Q1 2023, representing a significant decline[16] - The company's gross profit margin for Q1 2024 was approximately -8.8%, compared to a positive margin in the previous year[16] - The total comprehensive income for Q1 2024 was a loss of CNY 30.73 million, compared to a gain of CNY 94.88 million in the same period last year[17] Cash Flow - The net cash flow from operating activities improved by 64.87%, with a net outflow of ¥143,612,182.50 compared to a net outflow of ¥408,749,260.06 in the previous year[4] - The company reported a 41.65% decrease in cash inflows from operating activities, primarily due to reduced revenue[7] - Total cash inflow from operating activities decreased to 451,797,344.65 CNY, down 41.6% from 774,276,915.10 CNY in the previous period[18] - Cash outflow from operating activities also decreased to 595,409,527.15 CNY, down 49.7% from 1,183,026,175.16 CNY in the previous period[18] - The net cash flow from investing activities is -23,238,121.25 CNY, an improvement from -63,984,603.83 CNY in the previous period[19] - Cash inflow from investing activities increased to 20,806,243.66 CNY, compared to 8,606,841.20 CNY in the previous period[19] - Cash outflow from investing activities decreased to 44,044,364.91 CNY, down 39.4% from 72,591,445.03 CNY in the previous period[19] - The net cash flow from financing activities is -73,761,312.78 CNY, an improvement from -168,610,926.62 CNY in the previous period[19] - Cash inflow from financing activities decreased to 22,755,097.32 CNY, down 33.2% from 34,056,225.09 CNY in the previous period[19] - The ending cash and cash equivalents balance is 1,376,357,042.59 CNY, down from 2,822,735,743.35 CNY in the previous period[19] - The company’s cash and cash equivalents decreased by 239,639,024.47 CNY during the current period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,620,133,223.48, a decrease of 2.76% from ¥6,807,739,866.34 at the end of the previous year[4] - The total current assets decreased to RMB 4,142,000,005.65 from RMB 4,316,244,225.33, indicating a decline of approximately 4.0%[14] - Non-current assets totaled RMB 2,478,133,217.83, down from RMB 2,491,495,641.01, showing a decrease of about 0.5%[14] - The company's total liabilities decreased to CNY 1.74 billion in Q1 2024 from CNY 1.82 billion in the previous year[15] - The total equity attributable to shareholders of the parent company was CNY 4.07 billion, down from CNY 4.17 billion year-over-year[15] - The company reported a decrease in accounts payable to CNY 301.65 million from CNY 332.14 million in the previous year[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 46,370[10] - The company repurchased a total of 8,575,800 shares, resulting in an increase in treasury stock by ¥69,778,700[7] - The company's repurchase account held 8,575,800 shares, accounting for 1.67% of the total share capital as of the report date[11] - The company completed the transfer of 5% of its shares from Zhuhai Baolian Investment Holdings to Xi'an Zhitong Benyi Enterprise Management Partnership at a price of RMB 20 per share[12] - Xi'an Zhitong became the controlling shareholder after acquiring 25,715,859 shares, which represents 10.64% of the voting rights[12] - The board of directors was restructured, with Xi'an Zhitong nominating 5 out of 9 members, thus gaining substantial control over the company[12] Research and Development - Research and development expenses for Q1 2024 were CNY 47.23 million, a decrease of 28.2% from CNY 65.81 million in the same quarter last year[16]